Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01528046
Other study ID # MCC-16962
Secondary ID SP003
Status Completed
Phase Phase 1
First received
Last updated
Start date September 24, 2012
Est. completion date February 3, 2020

Study information

Verified date January 2023
Source H. Lee Moffitt Cancer Center and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the tolerability and safety of escalating doses of metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with recurrent and refractory solid tumors.


Description:

Metformin is an oral anti-diabetes medication that activates AMP-activated protein kinase (AMPK). Recent data from in vitro and in vivo experiments, as well as epidemiologic retrospective analyses, suggest that metformin has anti-cancer activity. Vincristine, irinotecan, and temozolomide (VIT) is a combination of chemotherapeutic agents that have different mechanisms of action as well as disparate side effect profiles. Two recent phase 1 trials have demonstrated that this regimen is safe and well-tolerated in children with relapsed and refractory solid tumors.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date February 3, 2020
Est. primary completion date September 26, 2019
Accepts healthy volunteers No
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: - Age: Patients must be > 1 year of age and = 18 years of age at time of initiation of protocol therapy. - Diagnosis: Patients have a histologically or radiographically confirmed relapsed or refractory solid tumor or primary central nervous system (CNS) malignancy. - Disease Status: Patients must have radiographically measurable disease. - Therapeutic Options: Patients must have relapsed or refractory cancers for which there is no known curative option or other available therapy proven to prolong survival with an acceptable quality of life. - Performance Level: Karnofsky = 50% for patients older than 16 years old, and Lansky = 50 for patients 1-16 years old. - Prior Therapy: Patients may have received prior therapy including vincristine, irinotecan, or temozolomide. Patients may not have previously been treated with combination therapy of irinotecan and temozolomide. - Patients must be fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. - Myelosuppressive chemotherapy: Patients must not have received myelosuppressive chemotherapy within 3 weeks of starting protocol therapy, or a minimum of six weeks must have elapsed since prior nitrosurea chemotherapy. - Hematopoietic growth factor: At least 7 days must have elapsed since the last administration of filgrastim, or 14 days since administration of pegfilgrastim. - Biologic (anti-neoplastic agent): At least 7 must have elapsed since the last administration of any biologic agent. - Radiation therapy (XRT): At least 14 days since the last dose of local palliative radiation therapy. Greater than 6 months must have elapsed since the last day of treatment if given total body irradiation, craniospinal irradiation. - Autologous or Allogenic Stem Cell Transplant: Complete resolution of graft versus host disease and no current need for immunosuppressive medication. Greater than 3 months must have elapsed since engraftment and no longer requiring transfusion of platelets or injection of colony stimulating factors. - Organ Function Requirements - Bone Marrow Function: Peripheral absolute neutrophil count (ANC) = 1000/µL; Platelet count = 100,000/µL (no platelet transfusion within 7 days prior to obtaining laboratory result); Hemoglobin = 8.0 gm/dL - Adequate Renal Function: Creatinine clearance or glomerular filtration rate = 70ml/min/1.73m^2 - Adequate Liver Function: Total bilirubin = 1.5x upper limit of normal (ULN) for age; alanine transaminase (ALT) = 5x ULN; Serum albumin = 2gm/dL - Informed Consent: All patients = 18 years of age must sign a written informed consent. For patients < 18 years old, the patient's parents or legal guardians must sign a written informed consent, unless the patient is an emancipated minor. Childhood Assent, when age appropriate as per institutional guidelines, should be signed by the participating patient. Exclusion Criteria: - Significant organ dysfunction, not meeting inclusion criteria. - Pregnancy or Breast-Feeding woman will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. - Concomitant Medications: - Growth factor: Growth factors that support platelet or white cell number of function must not have been administered within the past 7 days. - Steroids: Patients with CNS tumors who have not been on a stable or decreasing dose of dexamethasone for the past 7 days. - Investigational Drugs: Patients who are currently receiving another investigational drug. - Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents. - Medication Allergy: Allergy or intolerance to agents on this protocol: vincristine, irinotecan, temozolomide, or metformin; Allergy to cephalosporins. - Infection: Patients who have uncontrolled infection, positive blood cultures within the past 48 hours, or receiving treatment for Clostridium difficile infection.

Study Design


Intervention

Drug:
Vincristine
Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
Irinotecan
Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes
Temozolomide
Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5
Metformin
Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.

Locations

Country Name City State
United States Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland
United States The Children's Hospital at Montefiore Bronx New York
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Nationwide Children's Hospital Columbus Ohio
United States University of Florida Gainesville Florida
United States Connecticut Children's Medical Center Hartford Connecticut
United States Nemours Children's Clinic Jacksonville Florida
United States University of Kentucky Lexington Kentucky
United States University of Miami Sylvester Comprehensive Cancer Center Miami Florida
United States Johns Hopkins All Children's Hospital Saint Petersburg Florida
United States Primary Children's Medical Center/Utah Salt Lake City Utah
United States H. Lee Moffitt Cancer Center and Research Institute Tampa Florida
United States Tampa General Hospital Tampa Florida
United States Nemours/Alfred I. duPont Hospital for Children, Delaware Wilmington Delaware

Sponsors (2)

Lead Sponsor Collaborator
H. Lee Moffitt Cancer Center and Research Institute Pediatric Cancer Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) To determine the maximum tolerated dose (MTD) of metformin when given in conjunction with VIT in children with refractory and relapsed solid tumors. Average of 3 Months
Secondary Number of Participants with Antitumor Activity To evaluate the antitumor activity of the addition of metformin to VIT. Average of 3 Months
Secondary Pharmacokinetics To describe the pharmacokinetics of metformin in children with relapsed malignancies receiving VIT combination chemotherapy. Average of 3 Months
Secondary Pharmacodynamics To define the pharmacodynamics of metformin. Average of 3 Months
Secondary Metformin Concentrations To determine tissue and tumor metformin concentrations in patients undergoing resection. Average of 3 Months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00750841 - Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours Phase 1
Withdrawn NCT05419817 - Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Phase 2
Completed NCT02828930 - A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies) Phase 1
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Completed NCT03258515 - A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers Phase 1
Terminated NCT03225105 - M3541 in Combination With Radiotherapy in Solid Tumors Phase 1
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Completed NCT01878890 - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. Phase 1
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT03634982 - Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors Phase 1
Recruiting NCT04685226 - A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT06036121 - A Study of ADRX-0706 in Select Advanced Solid Tumors Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting NCT05325866 - A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Completed NCT02759640 - A Phase I Trial of HS-10241 in Solid Tumors Phase 1
Withdrawn NCT01940601 - Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors Phase 2
Completed NCT02279433 - A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Phase 1